BOSTON, Mass. and VANCOUVER, British Columbia, November 10, 2025 – Alpha-9 Oncology (“Alpha-9” or “the Company”), a clinical-stage radiopharmaceutical company developing targeted cancer therapies, today announced the appointment of Paul Blanchfield as Chief Executive Officer and a member of the Board of Directors. Mr.